Phase II Study of Everolimus in Refractory Testicular Germ Cell Cancer.

Trial Profile

Phase II Study of Everolimus in Refractory Testicular Germ Cell Cancer.

Completed
Phase of Trial: Phase II

Latest Information Update: 29 Apr 2016

At a glance

  • Drugs Everolimus (Primary)
  • Indications Testicular cancer
  • Focus Therapeutic Use
  • Most Recent Events

    • 11 Jan 2016 Status changed from recruiting to completed, as reported by ClinicalTrials.gov.
    • 02 Jun 2015 Primary endpoint has not been met. (Response rate), according to an abstract presented at the 51st Annual Meeting of the American Society of Clinical Oncology.
    • 02 Jun 2015 Results (n=15) presented at the 51st Annual Meeting of the American Society of Clinical Oncology.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top